公开(公告)号：US12145945B2

公开(公告)日：2024-11-19

申请号：US18600352

申请日：2024-03-08

Applicant: Breakpoint Therapeutics GmbH

Inventor： Andrea Guerrero Corella ,  Stuart Robert Flanagan ,  Jonathan Hollick ,  Julien Gilbert Jacques Malassis ,  Matthew Raymond Smith ,  Ian Andrew Yule ,  Jonathan Mark Bentley

IPC: C07D513/04 ,  A61K31/4545

Abstract: The present invention relates to a compound of the Formula: and pharmaceutically salts thereof. The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

公开(公告)号：US20240376090A1

公开(公告)日：2024-11-14

申请号：US18249774

申请日：2021-10-26

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Graeme Semple ,  Thuy-Anh Tran

IPC: C07D413/14 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/553 ,  C07D261/08 ,  C07D413/12 ,  C07D417/14 ,  C07D491/08 ,  C07D491/107 ,  C07D498/04

Abstract: Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, that is a modulator of 5-HT2A and can be used in treating diseases and disorders associated with 5-HT2A serotonin receptor expression and/or activity. Thus, also provided are methods of treating 5HT2A-related diseases and disorders.

公开(公告)号：US20240376073A1

公开(公告)日：2024-11-14

申请号：US18404194

申请日：2024-01-04

Applicant: Hoffmann-La Roche Inc.

Inventor： Sandra Marie Joseph GRALL-ULSEMER ,  Xingchun HAN ,  Joel Lukas KNECHT ,  Christian LERNER ,  Mingming LI ,  Yongqiang LIU ,  Patrizio MATTEI ,  Matthias NETTEKOVEN ,  Philippe PFLIEGER ,  Theodor STOLL ,  Jianhua WANG ,  Min WANG ,  Yongguang WANG ,  Song YANG ,  Chengang ZHOU

IPC: C07D401/12 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61P31/04 ,  C07C53/06 ,  C07C53/10 ,  C07D233/90 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D417/14 ,  C07D487/04

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as described herein: Frther provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

公开(公告)号：US20240374595A1

公开(公告)日：2024-11-14

申请号：US18776005

申请日：2024-07-17

Applicant: Arbutus Biopharma Corporation

Inventor： Yingzhi Bi ,  Bruce D. Dorsey ,  Yi Fan ,  Christopher Brooks Moore ,  Duyan Nguyen

IPC: A61K31/506 ,  A61K31/137 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/505 ,  A61K45/06 ,  C07C217/58 ,  C07C255/61 ,  C07D211/60 ,  C07D233/26 ,  C07D239/06 ,  C07D401/12 ,  C07D401/14

Abstract: The present invention includes substituted 3,3′-bis(phenoxymethyl)-1,1′-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

公开(公告)号：US20240374591A1

公开(公告)日：2024-11-14

申请号：US18573752

申请日：2022-06-24

Applicant: CELGENE CORPORATION

Inventor： Matthew D. ALEXANDER ,  Matthew D. CORREA ,  Deepak DALVIE ,  Virginia Heather Sharron GRANT ,  Joshua HANSEN ,  Roy L. HARRIS, III ,  Evan J. HORN ,  Dehua HUANG ,  Christopher MAYNE ,  Stephen NORRIS ,  Veronique PLANTEVIN-KRENITSKY ,  John J. SAPIENZA ,  Lida TEHRANI ,  Brandon W. WHITEFIELD

IPC: A61K31/506 ,  A61K31/4545 ,  A61K31/496 ,  A61P35/00 ,  C07D401/14

Abstract: Provided herein are piperidine dione compounds having the following structure: (I) wherein Y, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

公开(公告)号：US20240366575A1

公开(公告)日：2024-11-07

申请号：US18776516

申请日：2024-07-18

Applicant: Allergan Pharmaceuticals International Limited ,  Merck Sharp & Dohme Corp.

Inventor： Joel M. Trugman ,  Ramesh Boinpally ,  Abhijeet Jakate ,  Michelle Finnegan ,  Mary Ann Johnson ,  Leonardo R. Allain ,  W. Mark Eickhoff ,  Craig B. Ikeda ,  Chad D. Brown ,  Francis J. Flanagan, JR. ,  Rebecca Nofsinger ,  Melanie Marota ,  Lisa Lupton ,  Paresh B. Patel ,  Hanmi Xi ,  Wei Xu

IPC: A61K31/4375 ,  A61K31/4545 ,  A61P25/06

Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

公开(公告)号：US20240360109A1

公开(公告)日：2024-10-31

申请号：US18293637

申请日：2022-08-03

Applicant: SHANGHAI HANSOH BIOMEDICAL CO., LTD. ,  JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.

Inventor： Yidong Su ,  Xiaofeng Mao ,  Jun Wang ,  Xiaohan Zhou ,  Wensheng Yu

IPC: C07D405/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/538 ,  A61P3/04 ,  A61P3/10 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D405/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/538 ,  A61P3/04 ,  A61P3/10 ,  C07D413/14 ,  C07D471/04

Abstract: Provided are a polycyclic derivative regulator, a preparation method therefor, and an application thereof. In particular, provided are a compound represented by general formula (I′), a preparation method therefor, a pharmaceutical composition comprising the compound, and an application thereof as a regulator in the preparation of a drug for treating metabolic diseases and related diseases; the substituents in general formula (I′) are the same as those defined in the description.

公开(公告)号：US20240358695A1

公开(公告)日：2024-10-31

申请号：US18643177

申请日：2024-04-23

Applicant: Aurobindo Pharma Ltd

Inventor： Sreekanth Manikonda ,  Avinash Reddy Manda ,  Siva Kumar Reddy Chamala ,  Nagaprasad Vishnubhotla ,  Sivakumaran Meenakshisunderam

IPC: A61K31/4545 ,  A61K9/20

CPC classification number: A61K31/4545 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095

Abstract: The present invention relates to rapidly disintegrating pharmaceutical composition comprising Rimegepant or pharmaceutically acceptable salt thereof, and processes for manufacture thereof.

公开(公告)号：US12121540B2

公开(公告)日：2024-10-22

申请号：US17030335

申请日：2020-09-23

Applicant: Nurix Therapeutics, Inc.

Inventor： Jennifa Gosling ,  Arthur Sands ,  Sarah Anne Whelan ,  Cristiana Guiducci

IPC: A61K35/17 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/72 ,  C12N2506/11

Abstract: Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions using novel Cbl inhibitors for the propagation of cells desirable for use in cell-based immunotherapies.

公开(公告)号：US12121515B2

公开(公告)日：2024-10-22

申请号：US18366113

申请日：2023-08-07

Applicant: NeuroPn Therapeutics, Inc.

Inventor： Ish Khanna ,  Sivaram Pillarisetti

IPC: A61K31/4545 ,  A61K31/445 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61P25/02 ,  A61P25/16

CPC classification number: A61K31/4545 ,  A61K31/445 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61P25/02 ,  A61P25/16

Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.